Autoimmune and Inflammation Drug Targets

This conference focuses on small molecule and peptide or macrocyclic-based agents that have the potential to be developed into oral-based therapies for the treatment of autoimmune diseases and chronic inflammation disorders. The success of biologics for autoimmune diseases coupled with rapid advances in basic research has validated many immunology-relevant signaling pathways and uncovered new intracellular molecules to target for potential new drug agents that can enter the cell. Discovering oral-based therapies, which offer patient convenience, for autoimmune and inflammation conditions is a high priority in the drug discovery industry because of the chronic nature of many autoimmune and inflammation conditions and the fact that their incidence is predicted to steadily increase due to the growing aging population. Join CHI's Autoimmune and Inflammation Drug Targets conference to network with colleagues and stay abreast of this rapidly advancing field.


Who should attend: Immunologists, Discovery Biologists, Discovery Chemists from academic and pharmaceutical departments such as inflammation, immunology, autoimmune diseases, fibrosis, infectious diseases, molecular pharmacology, cardiometabolic diseases, and molecular pharmacology


Coverage will include, but is not limited to:                                        

  • Compounds in clinical trials for IBD, Lupus, MS and more
  • Nuclear hormone receptor targets (ROR, FXR)
  • Updates on promising new intracellular drug targets (inflammasome, complement cascade, mitochondrial proteins)
  • Immuno-modulatory agents (toll-like receptor (TLR) and sting agonists)
  • 2nd generation and new intracellular kinase inhibitors (JAK, BTK, RIPK, TYK2)


If you would like to submit a proposal to give a presentation at this meeting, please click here.


The deadline for priority consideration is March 21, 2018.


All proposals are subject to review by session chairmen and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.


For more details on the conference, please contact:
Anjani Shah, PhD

Conference Director

Cambridge Healthtech Institute

Phone: (+1) 781-247-6252


For partnering and sponsorship information, please contact:
Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286